Why the study?
Does finerenone reduce adverse renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus?
Does finerenone reduce adverse renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus?
Finerenone is advocated as an additional therapy to established treatments for reducing cardiorenal morbidity and mortality in high-risk patients with CKD and T2DM.
Patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) face considerable cardiorenal morbidity and mortality despite existing therapies. Recent clinical trials demonstrate the efficacy of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in reducing adverse renal and cardiovascular outcomes. This editorial briefly reviews the evidence and its implications for clinical practice, advocating the use of finerenone in these high-risk patients in combination with currently established treatment agents.
No takes yet. Share an insight, caveat, or question.
Manoharan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: